Standard BioTools (NASDAQ: LAB) warned on Nasdaq minimum bid-price compliance
Rhea-AI Filing Summary
Standard BioTools Inc. reported that Nasdaq’s Listing Qualifications Department notified the company on July 22, 2026 that its common stock no longer meets the $1.00 per share Minimum Bid Price Requirement for continued listing on the Nasdaq Global Select Market, after trading below that level for 30 consecutive business days.
The company has 180 calendar days, until January 19, 2027, to regain compliance by maintaining a closing bid price at or above $1.00 for at least 10 consecutive business days. Trading of the LAB common stock continues uninterrupted and business operations and SEC reporting are unaffected. Standard BioTools may seek an additional 180-day period by transferring to the Nasdaq Capital Market and meeting other listing standards, and it is working toward restoring compliance, though there is no assurance it will succeed or receive any extension.
Positive
- None.
Negative
- Nasdaq has notified the company it is out of compliance with the $1.00 minimum bid-price rule, putting its Nasdaq listing at risk if it cannot regain compliance by January 19, 2027.
Filing Explained
The company identifies a reverse stock split, if necessary, as one possible way to regain Nasdaq’s minimum bid-price compliance; that action would reduce the share count and proportionally raise the per-share price without changing company value by the split itself.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Minimum bid price threshold: $1.00 per share
Consecutive days below threshold: 30 business days
Initial compliance period: 180 calendar days
+2 more
5 metrics
Minimum bid price threshold
$1.00 per share
Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement for continued listing
Consecutive days below threshold
30 business days
Period during which the closing bid was below $1.00, triggering the notice
Initial compliance period
180 calendar days
Automatic grace period under Nasdaq rules to regain bid-price compliance
Compliance deadline
January 19, 2027
End of the initial 180-day period to meet the Minimum Bid Price Requirement
Required compliant trading period
10 consecutive business days
Minimum duration the bid must be at or above $1.00 to regain compliance
Key Terms
Minimum Bid Price Requirement, Nasdaq Global Select Market, Nasdaq Capital Market, reverse stock split, +1 more
5 terms
Minimum Bid Price Requirement regulatory
"did not meet the Minimum Bid Price Requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Global Select Market regulatory
"continued listing on The Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Nasdaq Capital Market regulatory
"transfer the listing of its common stock to The Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
reverse stock split financial
"for example, by implementing a reverse stock split, if necessary"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq notice did Standard BioTools (LAB) receive?
Nasdaq’s Listing Qualifications Department notified Standard BioTools that its stock failed the $1.00 Minimum Bid Price Requirement after 30 consecutive business days below that level, placing the company in noncompliance with continued listing standards.
What is the compliance deadline for Standard BioTools (LAB) to meet Nasdaq’s bid requirement?
Standard BioTools has until January 19, 2027 to regain compliance by keeping its closing bid at or above $1.00 for at least 10 consecutive business days during the 180-day grace period.
Does the Nasdaq deficiency notice immediately affect LAB stock trading?
The notice has no immediate effect on trading. Standard BioTools’ common stock continues to trade on the Nasdaq Global Select Market under the ticker LAB, and the company’s operations and SEC reporting obligations remain unchanged.
Can Standard BioTools (LAB) get more time beyond January 19, 2027 to regain compliance?
If it meets other listing standards, Standard BioTools may qualify for an additional 180-day compliance period by transferring to the Nasdaq Capital Market, subject to Nasdaq’s discretion and satisfaction of initial listing criteria except for bid price.
What steps might Standard BioTools (LAB) take to cure the Nasdaq bid-price deficiency?
The company indicates it intends to work toward restoring compliance and may, for example, implement a reverse stock split. Any transfer to the Nasdaq Capital Market would also require an application fee and written notice to Nasdaq.